Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8

References

• Lichtenstein AK, Levine A, Taylor CR, Boswell W, Ross-Man S, Feinstein DI, Lukes RJ. Primary mediastinal lymphoma in adults. Am J Med 1980; 68: 509–14
   PubMed Web of Science ®Google Scholar
• Moller P, Lammler B, Eberlein Gonska M, Feichter GE, Hofmann WJ, Schmitteckert H, Otto HF. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol 1986; 409: 79–92
   PubMedGoogle Scholar
• Moller P, Moldenhauer G, Momburg F, Lammler B, Eberlein Gonska M, Kiesel S, Dorken B. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood 1987; 69: 1087–95
   PubMed Web of Science ®Google Scholar
• Moller P, Matthaei Maurer DU, Hofmann WJ, Dorken B, Moldenhauer G. Immunophenotypic similarities of mediastinal clear-cell lymphoma and sinusoidal (monocytoid) B cells. Int J Cancer 1989; 43: 10–6
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994; 84: 1361–92
   PubMed Web of Science ®Google Scholar
• Paulli M, Lazzarino M, Gianelli U, Strater E, Orlandi E, Klersy C, Viglio A, Rosso R, Gambacorta M, Rousset T, Morra E, Lavabre Bertrand T, Bernasconi C, Manegold C, Magrini U Moller. P. Primary mediastinal B-cell lymphoma: update of its clinicopathologic features. Leuk Lymphoma 1997; 26, Suppl 1:115-23
   Web of Science ®Google Scholar
• Davis RE, Dorfman RF, Warnke RA. Primary large-cell lymphoma of the thymus: a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. Hum Pathol 1990; 21: 1262–8
   PubMed Web of Science ®Google Scholar
• Abou Elella AA, Weisenburger DD, Vose JM, Kollath JP, Lynch JC, Bast MA, Bierman PJ, Greiner TC, Chan WC, Armitage JO. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999; 17: 784–90
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, Gargantini L, Rousset MT, Gambacorta M, Marra E, Lavabre Bertrand T, Magrini U, Manegold C, Bernasconi C, Moller P. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multi-center study of 106 patients. J Clin Oncol 1915; 1997: 1646–53
   Google Scholar
• Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, De Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, Van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998; 16: 63–9
   PubMed Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91: 717–23
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Muller Weihrich S, Ritter J. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood 1992; 80: 2471–8
   PubMed Web of Science ®Google Scholar
• Cazals Hatem D, Lepage E, Brice P, Ferrant A, D'Agay MF, Baumelou E, Briere J, Blanc M., Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin J. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cel lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996; 20: 877–88
   PubMed Web of Science ®Google Scholar
• Brugger W, Engelhardt R, Mertelsmann R, Kanz L. The management of primary mediastinal B-cell lymphoma with sclerosis. Ann Oncol 1994; 5: 943–7
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Rodriguez Diaz Pavon J, Carias L, Hage-Meister FB, McLaughlin P, Rodriguez MA, Sarris AH, Younes A, Preti A, Bachier C, Llerena E, Cabanillas F. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma 1998; 28: 295–306
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Astori C, Paulli M, Magrini U, Bernasconi C. A low serum beta 2-microglobulin level despite bulky tumor is a characteristic feature of primary mediastinal (thymic) large B-cell lymphoma: implications for serologic staging [letter]. Eur J Haematol 1996; 57: 331–3
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, Kindl S, Rosso R, Astori C, Buonanno MC. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features [see comments]. J Clin Oncol 1993; 11: 2306–13
   PubMed Web of Science ®Google Scholar
• Menestrina F, Chilosi M, Bonetti F, Lestani M, Scarpa A, Novelli P, Doglioni C, Todeschini G, Ambrosetti A, Fiore Donati L. Mediastinal large-cell lymphoma of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases. Histopathology 1986; 10: 589–600
   PubMed Web of Science ®Google Scholar
• Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 casts. Am J Surg Pathol 1986; 10: 176–91
   PubMed Web of Science ®Google Scholar
• Vandenberghe P, Boogaerts MA. Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Ann Hematol 1995; 71: 209–17
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieu-Wenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–5
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690–5
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–53
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–5
   PubMed Web of Science ®Google Scholar
• Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituxi-mab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527–34
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266–74
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–95
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–52
   PubMed Web of Science ®Google Scholar
• Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89: 748–56
   PubMedGoogle Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med 1993; 329: 987–94
   PubMed Web of Science ®Google Scholar